Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 0.7% – Here’s Why

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shares traded up 0.7% on Friday . The company traded as high as $6.19 and last traded at $6.13. 7,806,536 shares traded hands during trading, an increase of 17% from the average session volume of 6,678,073 shares. The stock had previously closed at $6.09.

Wall Street Analysts Forecast Growth

Several research firms have commented on RXRX. Leerink Partners dropped their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research report on Tuesday, September 3rd. Needham & Company LLC reissued a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 11th. Finally, Jefferies Financial Group dropped their price target on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Tuesday, September 3rd. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, Recursion Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $9.25.

Recursion Pharmaceuticals Stock Up 0.8 %

The company’s 50 day simple moving average is $6.77 and its 200-day simple moving average is $7.22. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The firm has a market capitalization of $1.76 billion, a PE ratio of -4.01 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $26.08 million during the quarter, compared to analysts’ expectations of $12.62 million. During the same quarter last year, the business posted ($0.43) EPS. The company’s quarterly revenue was up 147.6% on a year-over-year basis. On average, analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Insider Transactions at Recursion Pharmaceuticals

In other news, CEO Christopher Gibson sold 20,000 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $6.16, for a total value of $123,200.00. Following the completion of the transaction, the chief executive officer now owns 762,656 shares of the company’s stock, valued at approximately $4,697,960.96. This represents a 2.56 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $7.00, for a total value of $42,000.00. Following the transaction, the chief operating officer now directly owns 521,138 shares of the company’s stock, valued at $3,647,966. This represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 107,788 shares of company stock worth $724,691. 15.75% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC purchased a new position in Recursion Pharmaceuticals in the 3rd quarter worth about $25,000. Farther Finance Advisors LLC raised its holdings in shares of Recursion Pharmaceuticals by 176.9% during the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock valued at $42,000 after purchasing an additional 4,091 shares during the last quarter. Amalgamated Bank boosted its holdings in Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after purchasing an additional 2,459 shares during the last quarter. KBC Group NV grew its position in Recursion Pharmaceuticals by 79.9% in the 3rd quarter. KBC Group NV now owns 7,602 shares of the company’s stock worth $50,000 after purchasing an additional 3,377 shares during the period. Finally, San Luis Wealth Advisors LLC purchased a new stake in Recursion Pharmaceuticals during the 3rd quarter valued at $69,000. 89.06% of the stock is owned by institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.